

POSTER PRESENTATION

Open Access

Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM)

Raffit Hassan^{1*}, Evan Alley², Hedy Kindler³, Scott Antonia⁴, Thierry Jahan⁵, Anish Thomas¹, Somayeh Honarmand⁶, Aimee L Murphy⁶, John J Grous⁷, Dirk G Brockstedt⁶

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

CRS-207 is live-attenuated, double-deleted *Listeria monocytogenes* (LADD) engineered to express the tumor-associated antigen mesothelin which is highly expressed in malignant pleural mesothelioma (MPM). CRS-207 stimulates potent innate and adaptive immunity and in combination with chemotherapy may act synergistically to alter the tumor environment to be more susceptible to immune-mediated killing. Preliminary data of 32 patients who received CRS-207 in combination with pemetrexed/cisplatin showed 60% partial responses and 94% disease control[1]. Low-dose cyclophosphamide (Cy) in combination with LADD improved immune and anti-tumor responses and overall survival in preclinical studies.

Methods

Up to 60 subjects are planned to be enrolled in 2 mutually exclusive, sequential cohorts at 5 clinical trial sites. Patients must be chemotherapy-naïve, have unresectable MPM, good performance status (ECOG 0 or 1) and adequate organ function. Eligible patients in Cohort 1 receive 2 prime vaccinations with CRS-207 (1×10^9 CFU; 250 mL IV over 2 hours) 2 weeks apart, followed by up to 6 cycles of pemetrexed (500 mg/m²) and cisplatin (75 mg/m²) 3 weeks apart and 2 CRS-207 boost vaccinations 3 weeks apart. Subjects are followed every 8 weeks until disease progression. Clinically stable patients continue CRS-207

maintenance vaccinations every 8 weeks. Patients in Cohort 2 receive low-dose Cy (200 mg/m²) 1 day prior to each CRS-207 vaccination. Objectives of the study are safety, immunogenicity, objective tumor responses and tumor marker kinetics.

Authors' details

¹Center for Cancer Research at the National Institutes of Health, Bethesda, MD, USA. ²University of Pennsylvania, Philadelphia, PA, USA. ³The University of Chicago Medicine, Chicago, IL, USA. ⁴H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. ⁵University of California San Francisco, San Francisco, CA, USA. ⁶Aduro Biotech Inc., Berkeley, CA, USA. ⁷Aduro Biotech Inc., Hopedale, MA, USA.

Published: 4 November 2015

Reference

1. Hassan, Antonia, Alley, et al: Mesothelin-targeted immunotherapy CRS-207 in combination with standard of care chemotherapy as treatment for malignant pleural mesothelioma (MPM). *J Clin Oncol* 2015, **33**(suppl), abstr 7565.

doi:10.1186/2051-1426-3-S2-P161

Cite this article as: Hassan et al: Anti-mesothelin vaccine CRS-207 with or without low-dose cyclophosphamide plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM). *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P161.

¹Center for Cancer Research at the National Institutes of Health, Bethesda, MD, USA

Full list of author information is available at the end of the article